PARIS–(BUSINESS WIRE)–Regulatory News: BioAlliance Pharma SA (Paris:BIO)(Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary …
[News Source]
Blogosphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg


